Scorpius Holdings achieves major milestone with cGMP facility validation

Scorpius Holdings announced the successful validation of its microbial facilities, marking a significant milestone in the Company’s operations. This validation signifies that Scorpius’ microbial cleanrooms are now officially approved to manufacture current Good Manufacturing Practice, cGMP, microbial biologic drugs, underscoring the Company’s commitment to quality and regulatory compliance. In conjunction with the facility qualifications, Scorpius is also streamlining its operations by transitioning environmental monitoring responsibilities to internal teams, while it migrates from the previous reliance on third-party services. “Scorpius has experienced strong interest in our microbial capabilities, and we continue to add additional opportunities to our pipeline for 2024 and 2025,” stated Jeff Wolf, CEO of Scorpius Holdings. “This validation confirms our commitment to high-quality, state-of-the-art microbial production. We are dedicated to leveraging our advanced capabilities to support our clients’ needs and contributing to the advancement of breakthrough therapies.”